Immediate determination of ACPA and rheumatoid factor - a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay

Arthritis Research and Therapy

Volumn 12, Issue 3, 2010, Pages

  Renger, Franziska ^a   Bang, Holger ^b   Feist, Eugen ^a   Fredenhagen, Gert ^b   Natusch, Alexander ^c   Backhaus, Marina ^a   Burmester, Gerd R ^a   Egerer, Karl ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ORGENTEC Diagnostika GmbH   (Germany)

^c MARTIN LUTHER KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; MUTATED AND CITRULLINATED VIMENTIN AUTOANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; VIMENTIN;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POINT OF CARE TESTING; PREDICTIVE VALUE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; AGED; BLOOD; EVALUATION; HOSPITAL INFORMATION SYSTEM; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POINT-OF-CARE SYSTEMS; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY; VIMENTIN;

EID: 77953673597     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3057     Document Type: Article

References (15)

1. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000, 39:28-33. 10.1093/rheumatology/39.1.28, 10662870.
2. Eberhardt K, Larsson BM, Nived K, Lindqvist E. Work disability in rheumatoid arthritis--development over 15 years and evaluation of predictive factors over time. J Rheumatol 2007, 34:481-487.
3. Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007, 56:2503-2511. 10.1002/art.22817, 17665451.
4. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R119. 10.1186/ar2008, 1779400, 16859519.
5. Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007, 53:498-504. 10.1373/clinchem.2006.078063, 17259232.
6. Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog L, Ronnelid J. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008, 58:36-45. 10.1002/art.23188, 18163519.
7. Soos L, Szekanecz Z, Szabo Z, Fekete A, Zeher M, Horvath IF, Danko K, Kapitany A, Vegvari A, Sipka S, Szegedi G, Lakos G. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 2007, 34:1658-1663.
8. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008, 35:1002-1008.
9. Nicaise Roland P, Grootenboer Mignot S, Bruns A, Hurtado M, Palazzo E, Hayem G, Dieude P, Meyer O, Chollet Martin S. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther 2008, 10:R142. 10.1186/ar2570, 2656247, 19077182.
10. Poulsom H, Charles PJ. Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clin Rev Allergy Immunol 2008, 34:4-10. 10.1007/s12016-007-8016-3, 18270850.
11. Ursum J, Nielen MM, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BA, Hamann D. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 2008, 10:R12. 10.1186/ar2362, 2374444, 18226202.
12. Wagner E, Skoumal M, Bayer PM, Klaushofer K. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int 2009, 29:1315-1321. 10.1007/s00296-009-0854-2, 19184032.
13. Chan KW, Felson DT, Yood RA, Walker AM. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994, 37:814-820. 10.1002/art.1780370606, 8003053.
14. Hernandez-Garcia C, Vargas E, Abasolo L, Lajas C, Bellajdell B, Morado IC, Macarron P, Pato E, Fernandez-Gutierrez B, Banares A, Jover JA. Lag time between onset of symptoms and access to rheumatology care and DMARD therapy in a cohort of patients with rheumatoid arthritis. J Rheumatol 2000, 27:2323-2328.
15. Snijders GF, Broeder AA, Bevers K, Jeurissen ME, van Eerd JE, van den Hoogen FH. Measurement characteristics of a new rapid anti-CCP2 test compared to the anti-CCP2 ELISA. Scand J Rheumatol 2008, 37:151-154. 10.1080/03009740701867331, 18415774.